ducovest

URE:ARCA-ProShares Ultra Real Estate

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 87.15

Change

+0.01 (+0.01)%

Market Cap

USD 0.18B

Volume

3.40K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Real EstateSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the real estate sector of the U.S. equity market. Component companies include, among others, real estate holding and development and real estate services companies and real estate investment trusts ("REITs"). The fund is non-diversified.

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 30/01/2007

Primary Benchmark: DJ US Real Estate TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.02%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
ASA ASA Gold and Precious Metals Ltd 3.59 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing URE

DKRB 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.60% 100% F 95% A
Dividend Return 0.66% 32% F 10% F
Total Return 56.26% 100% F 95% A
Trailing 12 Months  
Capital Gain 43.24% 95% A 95% A
Dividend Return 1.33% 56% F 24% F
Total Return 44.57% 95% A 95% A
Trailing 5 Years  
Capital Gain 94.90% 79% B- 88% B+
Dividend Return 6.96% 73% C 22% F
Total Return 101.86% 79% B- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 9.97% 76% C+ 80% B-
Dividend Return 11.06% 76% C+ 77% C+
Total Return 1.08% 62% D 25% F
Risk Return Profile  
Volatility (Standard Deviation) 15.61% 55% F 50% F
Risk Adjusted Return 70.84% 76% C+ 75% C
Market Capitalization 0.18B 76% C+ 26% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.